Entinostat (MS-275)

製品コードS1053 別名:SNDX-275

Entinostat (MS-275)化学構造

分子量(MW):376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 24900.00
JPY 44820.00
JPY 127820.00

文献中Selleckの製品使用例(62)

カスタマーフィードバック(14)

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

  • B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
ターゲット
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外試験

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NFfOPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml64TWM2OD1yLkC2NUDPxE1? M4fPXnNCVkeHUh?=
ALL-PO MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi1R4pKSzVyPUCuNFY{PTVizszN MVXTRW5ITVJ?
697 NF;HVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLyTFhsUUN3ME2wMlA6QTd4IN88US=> NFLiXHlUSU6JRWK=
NCI-H748 MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XyZWlEPTB;MD6xNFM{PCEQvF2= NELpZVFUSU6JRWK=
NKM-1 NH[xZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn4TWM2OD1yLkGwPVEzKM7:TR?= M{nFTHNCVkeHUh?=
ES1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjkdHlbUUN3ME2wMlEyOjV3IN88US=> MkHXV2FPT0WU
NCI-H1963 NIGw[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHQd21YUUN3ME2wMlEyPTd7IN88US=> MUfTRW5ITVJ?
NCI-H1417 NVnlc3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHTTWM2OD1yLkGyPVc1KM7:TR?= MYXTRW5ITVJ?
NEC8 NYDRdHR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMUO1Nlch|ryP MVTTRW5ITVJ?
CRO-AP2 M4DSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r4NGlEPTB;MD6xOlg5QSEQvF2= NVP2O|JwW0GQR1XS
A3-KAW MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXTTWM2OD1yLkG3OlI4KM7:TR?= Ml3OV2FPT0WU
SF539 M3PaO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF23O2pKSzVyPUCuNVk2QTNizszN M2Kz[HNCVkeHUh?=
NOS-1 MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LNemlEPTB;MD6xPVYyQSEQvF2= NHXsPGlUSU6JRWK=
NTERA-S-cl-D1 NHXQZ|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfrPWNuUUN3ME2wMlIxOTF|IN88US=> MlHHV2FPT0WU
COR-L88 M4LyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm2TWM2OD1yLkKyPVU6KM7:TR?= M2PKb3NCVkeHUh?=
EM-2 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jodmlEPTB;MD6yOFA4QSEQvF2= MlfnV2FPT0WU
KARPAS-45 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlviTWM2OD1yLkK3PFM{KM7:TR?= MmSzV2FPT0WU
DSH1 M4D0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T2bGlEPTB;MD6yPFcxQCEQvF2= NHzlZXBUSU6JRWK=
HT-144 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwM{CyOVYh|ryP NV\Fd5JLW0GQR1XS
ATN-1 NWTXZpJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf2TWM2OD1yLkOwOVc3KM7:TR?= MlfVV2FPT0WU
HEL NG\USodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfNW|hQUUN3ME2wMlMyOzR6IN88US=> M2rzTXNCVkeHUh?=
NB12 M4PUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M362OmlEPTB;MD6zNVc2PiEQvF2= NIPRbotUSU6JRWK=
LU-139 M4PqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwM{O1NUDPxE1? NXLjUpllW0GQR1XS
J-RT3-T3-5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\lRmtLUUN3ME2wMlM{PzF4IN88US=> M13DWHNCVkeHUh?=
MOLT-13 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwM{O4NUDPxE1? NWLvN2hrW0GQR1XS
SR MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\vTWM2OD1yLkO0NlYyKM7:TR?= MVXTRW5ITVJ?
CMK M3ntdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPBU4xKSzVyPUCuN|U4OjdizszN MWjTRW5ITVJ?
ES8 M1nPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP0UnBDUUN3ME2wMlM3ODJ{IN88US=> NVv0cJBZW0GQR1XS
LB647-SCLC NH21R5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jM[GlEPTB;MD6zOlc{KM7:TR?= NX7PfmdHW0GQR1XS
TE-8 M{TQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvBOYN{UUN3ME2wMlM3QTN3IN88US=> NGPabpZUSU6JRWK=
BV-173 M17KWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWexOZJRUUN3ME2wMlM4OTJzIN88US=> NEPXR3FUSU6JRWK=
DEL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPLWmZKSzVyPUCuN|c1QDdizszN NGHDR5VUSU6JRWK=
ARH-77 NHfXTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT6OGpKSzVyPUCuN|gyQTNizszN MYLTRW5ITVJ?
NCCIT MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HSUmlEPTB;MD6zPFY1QSEQvF2= MYrTRW5ITVJ?
RPMI-8402 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7qTWM2OD1yLkO4O|AyKM7:TR?= NVS5No1FW0GQR1XS
MONO-MAC-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwM{i3O|Yh|ryP NIXFV|FUSU6JRWK=
SK-MM-2 NGmwTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwM{m4Olgh|ryP MWrTRW5ITVJ?
CHP-126 NF;BW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3JdnNKSzVyPUCuOFAzOzFizszN MVHTRW5ITVJ?
A101D MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwNECzJO69VQ>? NVrxOWlYW0GQR1XS
SCH NY\qN|VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXHTWM2OD1yLkSwN|QzKM7:TR?= NWD6ephrW0GQR1XS
NMC-G1 NVT2U252T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwNECzOlch|ryP NXW3OZgxW0GQR1XS
NCI-H209 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvWTWM2OD1yLkSwOlE{KM7:TR?= NYXFfGFqW0GQR1XS
MOLT-16 NHPBZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwNEGwNVch|ryP NXzmVlNZW0GQR1XS
RPMI-6666 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnMNmZTUUN3ME2wMlQyOTJizszN NWnlZXliW0GQR1XS
OPM-2 NXXTZZp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPuZ|NKSzVyPUCuOFE2OTNizszN NIfrOGJUSU6JRWK=
MRK-nu-1 NVe0dWZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwNEOxOVMh|ryP NW[0O|VsW0GQR1XS
BC-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTZTWM2OD1yLkSzOFA{KM7:TR?= MUfTRW5ITVJ?
MHH-NB-11 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTVW2dVUUN3ME2wMlQ{PDV|IN88US=> M{DrSXNCVkeHUh?=
Ramos-2G6-4C10 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS2dmFKSzVyPUCuOFM5QTdizszN MXLTRW5ITVJ?
LS-513 M{THPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TtOGlEPTB;MD60OFUxOSEQvF2= NGC4fYdUSU6JRWK=
K5 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL1XWg4UUN3ME2wMlQ4ODJ3IN88US=> NY\wcVM2W0GQR1XS
HOP-62 NUTLbnFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jGSGlEPTB;MD60PFM2QCEQvF2= NGP4UHJUSU6JRWK=
NCI-H187 NIfUS|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwNEmyNlch|ryP MWXTRW5ITVJ?
BE-13 MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwNEm2OlEh|ryP NFKx[pBUSU6JRWK=
HC-1 NXXyfY9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7CTHBOUUN3ME2wMlUxPDd|IN88US=> M3W5fnNCVkeHUh?=
ACN NYG0WGRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\4cXZKSzVyPUCuOVExOjhizszN M4TufXNCVkeHUh?=
HCC1599 NGrVV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\xTWM2OD1yLkWxOVch|ryP MVfTRW5ITVJ?
MV-4-11 NUnDcppNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD5O5hKSzVyPUCuOVMxPDFizszN MlrzV2FPT0WU
LC-2-ad NG\oPVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT6TWM2OD1yLkWzOlY{KM7:TR?= NXvEOGllW0GQR1XS
HL-60 MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwNUSyOlEh|ryP NGn6OmpUSU6JRWK=
NB17 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG4[npKSzVyPUCuOVQ{QCEQvF2= NUW2R4tDW0GQR1XS
TE-1 Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwNUWzNFYh|ryP NHnMXYVUSU6JRWK=
NCI-H524 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7iR|RKSzVyPUCuOVU1ODFizszN MnfpV2FPT0WU
MZ7-mel NHfkSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfWeoRsUUN3ME2wMlU3OTB3IN88US=> NWTUU5E2W0GQR1XS
L-363 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jHbGlEPTB;MD61OlY2PyEQvF2= M2XsWnNCVkeHUh?=
BL-41 NETTepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwNU[4PFkh|ryP MnPPV2FPT0WU
LU-134-A M3LzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\ZTWM2OD1yLkW3NFc{KM7:TR?= MojlV2FPT0WU
SIG-M5 NXjrO3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3GVIdKSzVyPUCuOVc5PDhizszN Mln5V2FPT0WU
ONS-76 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXUbWtjUUN3ME2wMlU5OjR{IN88US=> MYTTRW5ITVJ?
KARPAS-299 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDsTWM2OD1yLkW4OVA1KM7:TR?= NUfrUVN[W0GQR1XS
DU-4475 M2T2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fBRWlEPTB;MD61PFcxOyEQvF2= NYTRN|FkW0GQR1XS
NB69 Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjXWoNxUUN3ME2wMlU6QDJ3IN88US=> MkDlV2FPT0WU
MHH-PREB-1 M2fLcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwNkC3NVkh|ryP M1XqZ3NCVkeHUh?=
LU-165 NWDPXY1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwNkG4NVIh|ryP MUjTRW5ITVJ?
LOUCY M1PnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTwfotKSzVyPUCuOlM{PjRizszN NHfndYhUSU6JRWK=
NCI-H526 NXzOemZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jjTWlEPTB;MD62N|U1OSEQvF2= M{nTSXNCVkeHUh?=
KE-37 NXeydnN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD2dGpDUUN3ME2wMlY1Ojd4IN88US=> M4XJR3NCVkeHUh?=
NALM-6 M4fiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwNkS4OkDPxE1? MYjTRW5ITVJ?
CW-2 Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO4TWM2OD1yLk[1O|k1KM7:TR?= NF:yZZlUSU6JRWK=
SU-DHL-1 NYThSINnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGzTWM2OD1yLk[1PVQ4KM7:TR?= NHjwcYlUSU6JRWK=
NB13 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T1dmlEPTB;MD62OlgyPyEQvF2= MUfTRW5ITVJ?
QIMR-WIL MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:5WGlEPTB;MD62PFM1OyEQvF2= MnK2V2FPT0WU
ECC12 M1TCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\hWYFKSzVyPUCuO|AxQDZizszN NH7nem9USU6JRWK=
KALS-1 NHzwNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwN{C0PVIh|ryP NUPW[Yl3W0GQR1XS
COR-L279 M4LtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnCbIJKSzVyPUCuO|A6QTZizszN NFzQSo9USU6JRWK=
NB14 NFv3OYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\YPGQ6UUN3ME2wMlczPjF5IN88US=> NXfIbGxHW0GQR1XS
CCRF-CEM NEnZNFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfYN|VKSzVyPUCuO|Q3PjFizszN MUHTRW5ITVJ?
SW954 MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DwfmlEPTB;MD63OVk6QSEQvF2= Ml;FV2FPT0WU
IST-SL1 NXTFRZE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrOSJZKSzVyPUCuO|c{PDhizszN M4jkOHNCVkeHUh?=
LAMA-84 NViybGp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwN{e1Olch|ryP M2TQVHNCVkeHUh?=
Daudi MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37kNGlEPTB;MD63O|Y5OSEQvF2= NV3qdlhjW0GQR1XS
BC-3 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwN{izNFgh|ryP Mn;4V2FPT0WU
HCC2998 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwN{izOkDPxE1? NVrEOXlbW0GQR1XS
NCI-H69 M{ji[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzJZ2xkUUN3ME2wMlgxOTR5IN88US=> MVrTRW5ITVJ?
CPC-N M2nV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T4R2lEPTB;MD64NFUzPCEQvF2= NXrBTHdYW0GQR1XS
NOMO-1 NVvGfGhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q1fmlEPTB;MD64NVA5PCEQvF2= NEXTPYlUSU6JRWK=
CESS MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwOEGxPVch|ryP NH;OToVUSU6JRWK=
LC4-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwOESwNFch|ryP NH7oVWZUSU6JRWK=
BL-70 NEPtTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwOEW3NFIh|ryP MWPTRW5ITVJ?
ES4 MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPSOnV{UUN3ME2wMlg2QDZ6IN88US=> MUTTRW5ITVJ?
HCE-T MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PMSmlEPTB;MD64O|E4OSEQvF2= MUXTRW5ITVJ?
JAR M1;RTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorBTWM2OD1yLki3PFI4KM7:TR?= M1\sU3NCVkeHUh?=
ST486 NIDFe4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPCTWM2OD1yLki3PVE4KM7:TR?= NH71RmRUSU6JRWK=
KS-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwOEiwPVYh|ryP MV7TRW5ITVJ?
GDM-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1n1PGlEPTB;MD64PFY5PyEQvF2= M3S5ZXNCVkeHUh?=
EHEB M{XWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS2TI9KSzVyPUCuPVI2QDVizszN MlKxV2FPT0WU
LB2518-MEL M{PWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwOUOyPFQh|ryP MU\TRW5ITVJ?
GOTO NUK0fpdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLVZ2VKSzVyPUCuPVUxPzZizszN M2rtbXNCVkeHUh?=
LXF-289 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zTOGlEPTB;MD65OVkxOSEQvF2= M1XrVXNCVkeHUh?=
ES6 NH;IZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrrSoIyUUN3ME2wMlk3PDN5IN88US=> M1rORnNCVkeHUh?=
OS-RC-2 M{\6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\yTWM2OD1yLkm2PFMh|ryP NILKe|RUSU6JRWK=
DMS-153 NFvhdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2wS29KSzVyPUCuPVc1PjlizszN MXLTRW5ITVJ?
SK-PN-DW M{jWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfRT2lKSzVyPUCuPVc5OzFizszN MkXkV2FPT0WU
HH NH3GdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwOUi5OVkh|ryP MnvUV2FPT0WU
SH-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFwMEK0NUDPxE1? NWDETVZDW0GQR1XS
MOLT-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\Bc2lEPTB;MT6wN|Q2PCEQvF2= NF\lUoZUSU6JRWK=
TGW NHrVO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jaUmlEPTB;MT6wO|Y4PSEQvF2= NEXtUJZUSU6JRWK=
L-540 NFjVVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOyTWM2OD1zLkGwOlA1KM7:TR?= MWPTRW5ITVJ?
PF-382 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWwWmZKSzVyPUGuNVE2OTNizszN NVvDPGUyW0GQR1XS
LC-1F M4\x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TEbGlEPTB;MT6xNlAxPyEQvF2= M1;LT3NCVkeHUh?=
OVCAR-4 NHHoZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwMUOxOlUh|ryP NUXpTZV2W0GQR1XS
A4-Fuk NXG1WIRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXGRZFkUUN3ME2xMlE2OzZ2IN88US=> MkLiV2FPT0WU
HCC2218 NFzWNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjMXZp7UUN3ME2xMlE3PjRzIN88US=> MkP4V2FPT0WU
HAL-01 MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfZN|JkUUN3ME2xMlE3QTR|IN88US=> MYXTRW5ITVJ?
IST-MEL1 NV7GfmI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMUe2OVkh|ryP NIHiT5lUSU6JRWK=
NCI-H719 NVTlUVJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr3SpdkUUN3ME2xMlE4QDl6IN88US=> NFj4NGZUSU6JRWK=
EVSA-T NGHhdIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXCdHFKSzVyPUGuNVgyOTRizszN MULTRW5ITVJ?
SK-NEP-1 NHP6bFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzhTWM2OD1zLkKwNlY3KM7:TR?= M1fNUXNCVkeHUh?=
OCUB-M MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHPb4xUUUN3ME2xMlIyPDh7IN88US=> NY\KWnVZW0GQR1XS
MEG-01 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFwMkKxNVgh|ryP Moe4V2FPT0WU
no-10 NXvOfHdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf2U5hUUUN3ME2xMlI{OTF{IN88US=> MVLTRW5ITVJ?
MHH-CALL-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jNXGlEPTB;MT6yOFczOSEQvF2= MV\TRW5ITVJ?
SK-N-DZ M1P0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf2d2w2UUN3ME2xMlI1Pzd4IN88US=> M{G4T3NCVkeHUh?=
SCLC-21H Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jYTWlEPTB;MT6yOlQ4QCEQvF2= M2P1[XNCVkeHUh?=
CTV-1 NICxWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnoR4tKSzVyPUGuNlc1OjVizszN MnzRV2FPT0WU
NB1 M{\UdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXBcnBLUUN3ME2xMlI4PzN{IN88US=> MXjTRW5ITVJ?
NCI-H64 MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLtNopGUUN3ME2xMlI5PDZ{IN88US=> MmSyV2FPT0WU
MDA-MB-134-VI MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmzTWM2OD1zLkK4OVc4KM7:TR?= NE\6VYNUSU6JRWK=
LB2241-RCC NG\acnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWwXmtKSzVyPUGuNlg3PjNizszN MVjTRW5ITVJ?
8-MG-BA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TCXWlEPTB;MT6yPFg3PiEQvF2= NWTNbnBoW0GQR1XS
LP-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvvTWM2OD1zLkK5PVQ4KM7:TR?= Mn7GV2FPT0WU
LS-411N NWXNc2JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPPTWM2OD1zLkOwPVk5KM7:TR?= MYLTRW5ITVJ?
CAL-148 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf5[5JUUUN3ME2xMlMzPTR{IN88US=> MkDBV2FPT0WU
NCI-H2171 MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDESGJKSzVyPUGuN|Q2ODJizszN M{TwbnNCVkeHUh?=
JiyoyeP-2003 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmxboU2UUN3ME2xMlM2OzlizszN MYXTRW5ITVJ?
NCI-H2107 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf6To0zUUN3ME2xMlM2QDh|IN88US=> Mon0V2FPT0WU
BB30-HNC M{PxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHGUGlrUUN3ME2xMlM5QTd6IN88US=> NHPhRlJUSU6JRWK=
K-562 M{C0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\HTWM2OD1zLkO5NlE6KM7:TR?= NHXZfpBUSU6JRWK=
PSN1 MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPiT2JQUUN3ME2xMlQzOjh5IN88US=> NIrx[4hUSU6JRWK=
HCC2157 NH;kOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwNEK2PVEh|ryP NWDRc2RRW0GQR1XS
SBC-1 M2Xj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PEUmlEPTB;MT60Nlc1OSEQvF2= NV\LRYNKW0GQR1XS
MC116 MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfITWM2OD1zLkSzOlE2KM7:TR?= M{PRNnNCVkeHUh?=
KARPAS-422 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmi3TWM2OD1zLkS1N|U5KM7:TR?= MkexV2FPT0WU
LB996-RCC M1XOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2mzTmlEPTB;MT60O|ExOyEQvF2= MVnTRW5ITVJ?
MSTO-211H NUjydXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTnfZdkUUN3ME2xMlQ4QTh5IN88US=> MWTTRW5ITVJ?
BT-474 MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rmOGlEPTB;MT61NVc3PCEQvF2= MV\TRW5ITVJ?
A388 MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jlT2lEPTB;MT61NVk1PSEQvF2= MUPTRW5ITVJ?
SJSA-1 NX\hPZNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDDdnJPUUN3ME2xMlUzOjZizszN NGDVc4FUSU6JRWK=
COLO-829 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;lZm9KSzVyPUGuOVM2PjRizszN NVPvU|JnW0GQR1XS
KM-H2 NFfG[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37scmlEPTB;MT61OlY4KM7:TR?= MUXTRW5ITVJ?
GR-ST NVW1dGNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\CZZp{UUN3ME2xMlU3QDJizszN M2GxcXNCVkeHUh?=
RPMI-8866 M4PUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS5OmxvUUN3ME2xMlYxOTR2IN88US=> NFXBXWFUSU6JRWK=
KG-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITkbVNKSzVyPUGuOlE6ODFizszN MUDTRW5ITVJ?
NCI-H82 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPVTWM2OD1zLk[zOFA3KM7:TR?= NWT0enZLW0GQR1XS
LB1047-RCC NWTXUXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTMXFVKSzVyPUGuOlM1PTlizszN NVz1WmFZW0GQR1XS
KM12 M33sS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rldmlEPTB;MT62OFch|ryP M{XDVnNCVkeHUh?=
NB5 NVvTdYx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwNkW2O|ch|ryP NULLfJIzW0GQR1XS
HDLM-2 M1WwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTSTWM2OD1zLk[4NlgyKM7:TR?= NF7O[4lUSU6JRWK=
KU812 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwNkm2NFUh|ryP NH\HUlFUSU6JRWK=
DB NFv4fmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzFb4ROUUN3ME2xMlcxOzV|IN88US=> MorKV2FPT0WU
HD-MY-Z Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljzTWM2OD1zLke1NlM1KM7:TR?= NYf5[mlMW0GQR1XS
KURAMOCHI MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PFVWlEPTB;MT63O|IxPyEQvF2= NFnaXHdUSU6JRWK=
ETK-1 MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXQTWM2OD1zLke4PFc6KM7:TR?= M2jLWnNCVkeHUh?=
SK-UT-1 NGPD[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXwdpRKSzVyPUGuO|k{QDhizszN Mo\1V2FPT0WU
HUTU-80 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3pTWM2OD1zLke5OVA5KM7:TR?= M4TJNnNCVkeHUh?=
ES7 NFjaXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTFwOECzNFIh|ryP NYrLPVVoW0GQR1XS
SW872 M1fhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofxTWM2OD1zLkixN|k2KM7:TR?= NF6xZnlUSU6JRWK=
TK10 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILYVlJKSzVyPUGuPFMyODhizszN MkS4V2FPT0WU
LB831-BLC MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrKcZJKSzVyPUGuPFM2PjNizszN MlixV2FPT0WU
TE-9 M2rBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW5TWM2OD1zLki0OFIzKM7:TR?= NGHXd|dUSU6JRWK=
MLMA MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInwU3NKSzVyPUGuPFgzOzRizszN MVrTRW5ITVJ?
D-542MG MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFwOEmzO|Mh|ryP Mn;BV2FPT0WU
EW-16 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID4UHhKSzVyPUGuPVI4OiEQvF2= M3zhVHNCVkeHUh?=
LOXIMVI MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFwOUOyPEDPxE1? MkTHV2FPT0WU
GB-1 NHfxcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELx[pJKSzVyPUGuPVM5PjZizszN NXrHZoFEW0GQR1XS
IST-SL2 NXHkSYhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzZTWM2OD1{LkCwNlYzKM7:TR?= MlTiV2FPT0WU
LAN-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknYTWM2OD1{LkCxPVY3KM7:TR?= NF:2[oRUSU6JRWK=
NCI-H510A NIDKeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJwMES1NFIh|ryP M4LVenNCVkeHUh?=
NCI-H1092 M1P5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXtOlJKSzVyPUKuNFUyOjRizszN MkDZV2FPT0WU
HT NHi1TmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrzXI9KSzVyPUKuNVA1PTRizszN M2mwNXNCVkeHUh?=
RL95-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfj[JpKSzVyPUKuNVE1QDJizszN MV3TRW5ITVJ?
NCI-H1355 M{nIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTxTWM2OD1{LkGxO|kzKM7:TR?= MVfTRW5ITVJ?
NCI-H720 NXXzcGdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX0blhKSzVyPUKuNVY5PzNizszN NVLafJA5W0GQR1XS
NCI-H1522 NXfCfXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXXTWM2OD1{LkKxO|I{KM7:TR?= NGfTeFhUSU6JRWK=
LB373-MEL-D M2jodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwMk[5NFIh|ryP NWDmPFRnW0GQR1XS
DG-75 NUPSUXljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfMTWM2OD1{LkK3NVQ5KM7:TR?= M1PoTnNCVkeHUh?=
ML-2 NFjqSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJwM{K4OVUh|ryP NXHnVGU4W0GQR1XS
SF126 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fDRWlEPTB;Mj6zN|A6PCEQvF2= MnXqV2FPT0WU
MPP-89 NX3YUJN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;wTWM2OD1{LkOzNVQ2KM7:TR?= M2rhO3NCVkeHUh?=
NCI-H345 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJwM{OyO|ch|ryP NWXSSmVlW0GQR1XS
LS-123 NGPWVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLBTWM2OD1{LkO0PVM3KM7:TR?= MoDnV2FPT0WU
NB10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHSXHMzUUN3ME2yMlQyODl{IN88US=> MmjlV2FPT0WU
CGTH-W-1 NInCRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDtTWM2OD1{LkSyNlY4KM7:TR?= M16yfnNCVkeHUh?=
CP66-MEL M1jyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLzTWM2OD1{LkS3O|ch|ryP MoLZV2FPT0WU
L-428 NXrmTok3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJwNEi1NlEh|ryP M13FTXNCVkeHUh?=
DMS-79 M1e2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nFdWlEPTB;Mj61OFExOyEQvF2= NHjG[5FUSU6JRWK=
NCI-H1882 NX7UZ4RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i1ZmlEPTB;Mj62O|U3OiEQvF2= MY\TRW5ITVJ?
KGN NXvsWmVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj2UIxGUUN3ME2yMlc3QDd4IN88US=> NVnNRnVZW0GQR1XS
EW-1 M2KzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7wcnRKSzVyPUKuO|cxQDNizszN M33FTHNCVkeHUh?=
U-266 NUm4OZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rrT2lEPTB;Mj64OFgzOyEQvF2= NW\X[Yh2W0GQR1XS
COLO-320-HSR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJwOEW2OFEh|ryP MXHTRW5ITVJ?
KMOE-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rofmlEPTB;Mj64O|cyOSEQvF2= MYjTRW5ITVJ?
BB49-HNC NYmyXolIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PEfGlEPTB;Mj65NlQ5KM7:TR?= MYfTRW5ITVJ?
GI-1 NWjuRpVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLaTWM2OD1{LkmyPVU4KM7:TR?= NUXKXotGW0GQR1XS
NCI-H1304 M2rKdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M32yN2lEPTB;Mz6wNFUyOSEQvF2= NInUUFhUSU6JRWK=
NCI-H2227 M1K5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LxcmlEPTB;Mz6wNlA4QSEQvF2= M36xSXNCVkeHUh?=
U-87-MG NH32XHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nV[WlEPTB;Mz6wN|UyOyEQvF2= M3HFeXNCVkeHUh?=
NCI-H747 NXLNNWFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\qTWM2OD1|LkC1NlA3KM7:TR?= NHj2[45USU6JRWK=
CTB-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNwMEWzO|Yh|ryP MUfTRW5ITVJ?
RPMI-8226 M4\BeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTNwMUSzO|gh|ryP NGfYTZhUSU6JRWK=
NCI-H2141 MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\iTWM2OD1|LkG2OVY3KM7:TR?= NHfmdIlUSU6JRWK=
IST-MES1 M3\FZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\tTWM2OD1|LkG4Nlc6KM7:TR?= NEHQcWNUSU6JRWK=
TE-5 NFzRc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TIPGlEPTB;Mz6yNVM1OiEQvF2= NGjDfXNUSU6JRWK=
UACC-257 NXfrOVdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDrTWM2OD1|LkSzOlU6KM7:TR?= MorRV2FPT0WU
SK-N-FI NWTx[4QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfWRlJKSzVyPUOuOFUzOjdizszN NH64VXhUSU6JRWK=
MFH-ino NXzvcYpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TCWGlEPTB;Mz60OlU5QSEQvF2= M1i2RXNCVkeHUh?=
SF268 NHHXNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\TTWM2OD1|LkS4NVc1KM7:TR?= NHvDN4lUSU6JRWK=
TE-12 NITPVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3NmlEPTB;Mz61NVY6QSEQvF2= NX[yeIxnW0GQR1XS
NB6 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDIbo1KSzVyPUOuOVU2PjNizszN M{LOOHNCVkeHUh?=
DJM-1 MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HnSmlEPTB;Mz61PVg6QSEQvF2= NGjjU2lUSU6JRWK=
MZ1-PC MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi4WFdKSzVyPUOuOlE3OjRizszN MkTKV2FPT0WU
OCI-AML2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HBZWlEPTB;Mz62NlY4OSEQvF2= MWPTRW5ITVJ?
NCI-H1155 M13rZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTNwN{C5OFch|ryP NGLhdI1USU6JRWK=
RKO M4rId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr3b2NIUUN3ME2zMlc4OTh7IN88US=> NU[zNXU6W0GQR1XS
ECC4 NG[3XZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\vTWM2OD1|Lkm3NVk2KM7:TR?= MlrSV2FPT0WU
BB65-RCC M2Hyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNwOUe1OFch|ryP NGmyN2pUSU6JRWK=
EB-3 M1e2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fzVmlEPTB;Mz65PVY{OyEQvF2= MUXTRW5ITVJ?
SHP-77 NWG0S45yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTRwMEC1NlQh|ryP NHvtZnNUSU6JRWK=
NCI-H2196 NInVXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XC[WlEPTB;ND6wOVYzPSEQvF2= M{fOUHNCVkeHUh?=
GI-ME-N NVPYU2U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;hTWM2OD12LkC2N|k6KM7:TR?= NHnobINUSU6JRWK=
MN-60 NUe0NHRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrzNHp[UUN3ME20MlExQDdizszN M1z4XHNCVkeHUh?=
NCI-H1694 M3K1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWxWXpnUUN3ME20MlE{PDB3IN88US=> NUH6ToVIW0GQR1XS
LU-65 NUfjT|VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXYSYxKSzVyPUSuNVU{OzJizszN MUPTRW5ITVJ?
NCI-H1436 NEmyN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLVVHNPUUN3ME20MlE5OzN|IN88US=> NGX1emJUSU6JRWK=
KINGS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37MVWlEPTB;ND6zNVQ{OiEQvF2= Mm\SV2FPT0WU
GT3TKB Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTRwM{OyOlgh|ryP M37iZ3NCVkeHUh?=
Becker MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfqTmhZUUN3ME20MlM4OzF{IN88US=> M2XBcnNCVkeHUh?=
HCC1187 NGXCOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfxTlYxUUN3ME20Mlg6PjV5IN88US=> NHvrdY1USU6JRWK=
D-502MG MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\LSG9sUUN3ME21MlAxPDF4IN88US=> MV\TRW5ITVJ?
VA-ES-BJ NXHmOm5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPiOGJKSzVyPUWuNVM4PzhizszN M3TsN3NCVkeHUh?=
NB7 M3\6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTVwMUSxNVIh|ryP MXfTRW5ITVJ?
SW962 NVfJN3NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XrZWlEPTB;NT6zPFgyPCEQvF2= M3:wN3NCVkeHUh?=
no-11 MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPHSoxvUUN3ME21Mlc3OzR|IN88US=> NFjMfZhUSU6JRWK=
KNS-81-FD M1T3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnMTWM2OD13LkmwOlk1KM7:TR?= MXjTRW5ITVJ?
COLO-684 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTVwOUm0PVQh|ryP NI\lSGVUSU6JRWK=
D-263MG MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\mWGlEPTB;Nj6wPFg6PSEQvF2= NHfTfYJUSU6JRWK=
EW-24 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\FSG5wUUN3ME22MlI5PTFizszN MXTTRW5ITVJ?
TE-10 NETDfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLITWM2OD14LkSyOlI{KM7:TR?= MXXTRW5ITVJ?
EKVX MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Pnd2lEPTB;Nj60OlMzOSEQvF2= MWnTRW5ITVJ?
NCI-H1648 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\xU2lEPTB;Nj62O|U2PyEQvF2= NYXBboVFW0GQR1XS
LB771-HNC NXn3fZZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPhVXlKSzVyPU[uPVI{ODFizszN MVzTRW5ITVJ?
SK-MEL-1 NEPwcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRThwMUOxOlYh|ryP M3zre3NCVkeHUh?=
COLO-668 NXXqb3R6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRThwMke3PFYh|ryP MVHTRW5ITVJ?
EW-12 M4XKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRThwNEC4NFMh|ryP M3zGNnNCVkeHUh?=
A253 NInYcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPJTWM2OD16Lki0OlYyKM7:TR?= MV7TRW5ITVJ?
NCI-H2126 NVnBUFdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRThwOEmzNVkh|ryP MVvTRW5ITVJ?
Calu-6 NVzTWplQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRThwOUmwOFIh|ryP NFvac2lUSU6JRWK=
NCI-H23 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX2[olpUUN3ME25MlE4PzR4IN88US=> MUHTRW5ITVJ?
WSU-NHL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTlwN{e0O|gh|ryP M4TyPHNCVkeHUh?=
MMAC-SF NUHuRnJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr0PIhKSzVyPUmuPVc6ODRizszN NYiw[2VVW0GQR1XS
SK-LMS-1 MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFyLkK4N|Qh|ryP MUfTRW5ITVJ?
GCIY MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK0dIVKUUN3ME2xNE42QTJ2IN88US=> Mn30V2FPT0WU
TE-15 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\XXGlEPTB;MUGuOlAxPCEQvF2= NVu4V2RWW0GQR1XS
EoL-1-cell MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfYXndKSzVyPUGxMlc3QDJizszN M{LWVHNCVkeHUh?=
NCI-H2081 M1j4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:xU2dKSzVyPUGxMlc4QDZizszN NWjPfXNwW0GQR1XS
EW-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF{LkK0OlMh|ryP MYTTRW5ITVJ?
CAS-1 M1nDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrH[5NKSzVyPUGyMlM3OzFizszN NVflfFlMW0GQR1XS
C2BBe1 NIfrPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjBRolWUUN3ME2xNk43OTNzIN88US=> MmnPV2FPT0WU
D-247MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHYTWM2OD1zMj63PVUzKM7:TR?= NYDFb5dpW0GQR1XS
NCI-SNU-5 NEjUN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rFUGlEPTB;MUKuPFAyOyEQvF2= NGfTdXdUSU6JRWK=
LS-1034 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF2LkO5O|Uh|ryP MU\TRW5ITVJ?
EW-18 NYqzc4NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF2LkS0PEDPxE1? M3zDfHNCVkeHUh?=
Raji Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XG[2lEPTB;MUSuOVA1QSEQvF2= MYHTRW5ITVJ?
D-283MED MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D4cWlEPTB;MUSuOlI4OSEQvF2= NGruclFUSU6JRWK=
MZ2-MEL NYq4SW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuybI5GUUN3ME2xOE46Pjl4IN88US=> M3noOHNCVkeHUh?=
NCI-SNU-16 NYnPdWFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\FdI5KSzVyPUG1MlQ3OzNizszN NXvtXW5zW0GQR1XS
P30-OHK NFzEXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTYTWM2OD1zNz63PFMyKM7:TR?= NHj2U3BUSU6JRWK=
RXF393 NF;MbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLpZ3BKSzVyPUG5MlAyQDZizszN MWXTRW5ITVJ?
NCI-H1395 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7sb|NrUUN3ME2yNE43PzB|IN88US=> MYjTRW5ITVJ?
U-698-M MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\NVWlEPTB;MkCuO|A4PSEQvF2= MkHtV2FPT0WU
NCI-SNU-1 NFrCfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu4SIhKSzVyPUKwMlczOjNizszN M1TKdnNCVkeHUh?=
SW684 NYDYclZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJzLkG3NVYh|ryP MnHiV2FPT0WU
NCI-H716 Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHRZYRKSzVyPUKxMlMyPTRizszN NXL6RmNoW0GQR1XS
JVM-2 NWi0OpBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6zTWM2OD1{MT60NVM{KM7:TR?= MWfTRW5ITVJ?
NCI-H1581 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LQNWlEPTB;MkKuOFE1QCEQvF2= MmTSV2FPT0WU
CA46 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PifmlEPTB;M{GuOlk{PiEQvF2= MmSyV2FPT0WU
SNB75 NYnlZlROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTN|Lk[1NFMh|ryP NE\afXhUSU6JRWK=
KNS-42 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jY[mlEPTB;M{WuPVYzPCEQvF2= NUe5PZBSW0GQR1XS
TUR NHLLem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz2TWM2OD1|Nj6wOVIyKM7:TR?= MlTvV2FPT0WU
REH MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrGWlVKSzVyPUO3MlgzOTFizszN NHiwbFJUSU6JRWK=
EW-22 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDEUJhUUUN3ME20Nk4zQDh3IN88US=> NV7sUIJTW0GQR1XS
NCI-H446 NF\uOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXXUZhKSzVyPUSyMlc5PTNizszN M3[zNnNCVkeHUh?=
ES3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i1UmlEPTB;NEOuNVM{QSEQvF2= NE\2fZJUSU6JRWK=
EW-11 NXH6XYVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz2TWM2OD12ND64NlE5KM7:TR?= MYrTRW5ITVJ?
RH-1 NYfwemh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLFcGJKSzVyPUS3MlU5OTJizszN M122[3NCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[6]

+ 展開

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
細胞試験:

[2]

+ 展開
  • 細胞株: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • 濃度: ~ 10 μM
  • 反応時間: 3 days
  • 実験の流れ:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • 製剤: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • 投薬量: 12.3, 24.5 and 49 mg/kg
  • 投与方法: Administered orally once daily 5 days per week for 4 weeks
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 376.41
化学式

C21H20N4O3

CAS No. 209783-80-2
保管
in solvent
別名 SNDX-275

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03473639 Recruiting Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals December 15 2018 Phase 1
NCT03552380 Recruiting Renal Cell Carcinoma Roberto Pili|Bristol-Myers Squibb|Syndax Pharmaceuticals|Indiana University School of Medicine|Hoosier Cancer Research Network August 31 2018 Phase 2
NCT03538171 Recruiting Advanced Breast Cancer EddingPharm Oncology Co. LTD. May 15 2018 Phase 3
NCT03501381 Recruiting Renal Cell Carcinoma Roberto Pili|Indiana University Melvin and Bren Simon Cancer Center|Prometheus Laboratories|Syndax Pharmaceuticals|Hoosier Cancer Research Network May 24 2018 Phase 2
NCT02697630 Recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals February 21 2018 Phase 2
NCT03361800 Recruiting Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) January 22 2018 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Entinostat (MS-275)を買う | Entinostat (MS-275) ic50 | Entinostat (MS-275)供給者 | Entinostat (MS-275)を購入する | Entinostat (MS-275)費用 | Entinostat (MS-275)生産者 | オーダーEntinostat (MS-275) | Entinostat (MS-275)化学構造 | Entinostat (MS-275)分子量 | Entinostat (MS-275)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID